Market Analysis and Insights: Global Oral Anti-diabetes Drugs Market
The research report studies the Oral Anti-diabetes Drugs market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Oral Anti-diabetes Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Oral Anti-diabetes Drugs Scope and Segment
The global Oral Anti-diabetes Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oral Anti-diabetes Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
by Type
Liquid
Capsule
Tablet
by Drug Class
Sulfonylureas
Meglitinides
Biguanides
Others
by Distribution Channel, this report covers the following segments
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oral Anti-diabetes Drugs market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Oral Anti-diabetes Drugs key players in this market include:
Sanofi
Eli Lilly
AstraZeneca plc
Astellas Pharma Inc
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Abbott
Biocon
Sunpharma
Novo Nordisk
Piramal Healthcare
Bayer Healthcare
Dr. Reddy’s Laboratories Ltd
Glenmark Pharmaceuticals Ltd
The research report studies the Oral Anti-diabetes Drugs market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Oral Anti-diabetes Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Oral Anti-diabetes Drugs Scope and Segment
The global Oral Anti-diabetes Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oral Anti-diabetes Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
by Type
Liquid
Capsule
Tablet
by Drug Class
Sulfonylureas
Meglitinides
Biguanides
Others
by Distribution Channel, this report covers the following segments
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Oral Anti-diabetes Drugs market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Oral Anti-diabetes Drugs key players in this market include:
Sanofi
Eli Lilly
AstraZeneca plc
Astellas Pharma Inc
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Abbott
Biocon
Sunpharma
Novo Nordisk
Piramal Healthcare
Bayer Healthcare
Dr. Reddy’s Laboratories Ltd
Glenmark Pharmaceuticals Ltd
1 Market Overview of Oral Anti-diabetes Drugs
1.1 Oral Anti-diabetes Drugs Market Overview
1.1.1 Oral Anti-diabetes Drugs Product Scope
1.1.2 Oral Anti-diabetes Drugs Market Status and Outlook
1.2 Global Oral Anti-diabetes Drugs Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Oral Anti-diabetes Drugs Market Size by Region (2016-2027)
1.4 Global Oral Anti-diabetes Drugs Historic Market Size by Region (2016-2021)
1.5 Global Oral Anti-diabetes Drugs Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.1 North America Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.2 Europe Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.4 Latin America Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.5 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2016-2027)
2 Oral Anti-diabetes Drugs Market Overview by Type
2.1 Global Oral Anti-diabetes Drugs Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2016-2021)
2.3 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2022-2027)
2.4 Liquid
2.5 Capsule
2.6 Tablet
3 Oral Anti-diabetes Drugs Market Overview by Distribution Channel
3.1 Global Oral Anti-diabetes Drugs Market Size by Distribution Channel: 2016 VS 2021 VS 2027
3.2 Global Oral Anti-diabetes Drugs Historic Market Size by Distribution Channel (2016-2021)
3.3 Global Oral Anti-diabetes Drugs Forecasted Market Size by Distribution Channel (2022-2027)
3.4 Hospital Pharmacies
3.5 Retail Pharmacies
3.6 Online Pharmacies
4 Oral Anti-diabetes Drugs Competition Analysis by Players
4.1 Global Oral Anti-diabetes Drugs Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2020)
4.3 Date of Key Players Enter into Oral Anti-diabetes Drugs Market
4.4 Global Top Players Oral Anti-diabetes Drugs Headquarters and Area Served
4.5 Key Players Oral Anti-diabetes Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Oral Anti-diabetes Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi
5.1.1 Sanofi Profile
5.1.2 Sanofi Main Business
5.1.3 Sanofi Oral Anti-diabetes Drugs Products, Services and Solutions
5.1.4 Sanofi Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.1.5 Sanofi Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Oral Anti-diabetes Drugs Products, Services and Solutions
5.2.4 Eli Lilly Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.2.5 Eli Lilly Recent Developments
5.3 AstraZeneca plc
5.3.1 AstraZeneca plc Profile
5.3.2 AstraZeneca plc Main Business
5.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Products, Services and Solutions
5.3.4 AstraZeneca plc Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.3.5 Astellas Pharma Inc Recent Developments
5.4 Astellas Pharma Inc
5.4.1 Astellas Pharma Inc Profile
5.4.2 Astellas Pharma Inc Main Business
5.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Products, Services and Solutions
5.4.4 Astellas Pharma Inc Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.4.5 Astellas Pharma Inc Recent Developments
5.5 Johnson & Johnson (Janssen Pharmaceuticals)
5.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Profile
5.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Main Business
5.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Products, Services and Solutions
5.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Products, Services and Solutions
5.6.4 Boehringer Ingelheim Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Oral Anti-diabetes Drugs Products, Services and Solutions
5.7.4 Merck Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.7.5 Merck Recent Developments
5.8 Takeda
5.8.1 Takeda Profile
5.8.2 Takeda Main Business
5.8.3 Takeda Oral Anti-diabetes Drugs Products, Services and Solutions
5.8.4 Takeda Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.8.5 Takeda Recent Developments
5.9 Bristol Myers Squibb
5.9.1 Bristol Myers Squibb Profile
5.9.2 Bristol Myers Squibb Main Business
5.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Products, Services and Solutions
5.9.4 Bristol Myers Squibb Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.9.5 Bristol Myers Squibb Recent Developments
5.10 Novartis
5.10.1 Novartis Profile
5.10.2 Novartis Main Business
5.10.3 Novartis Oral Anti-diabetes Drugs Products, Services and Solutions
5.10.4 Novartis Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.10.5 Novartis Recent Developments
5.11 Pfizer
5.11.1 Pfizer Profile
5.11.2 Pfizer Main Business
5.11.3 Pfizer Oral Anti-diabetes Drugs Products, Services and Solutions
5.11.4 Pfizer Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.11.5 Pfizer Recent Developments
5.12 Abbott
5.12.1 Abbott Profile
5.12.2 Abbott Main Business
5.12.3 Abbott Oral Anti-diabetes Drugs Products, Services and Solutions
5.12.4 Abbott Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.12.5 Abbott Recent Developments
5.13 Biocon
5.13.1 Biocon Profile
5.13.2 Biocon Main Business
5.13.3 Biocon Oral Anti-diabetes Drugs Products, Services and Solutions
5.13.4 Biocon Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.13.5 Biocon Recent Developments
5.14 Sunpharma
5.14.1 Sunpharma Profile
5.14.2 Sunpharma Main Business
5.14.3 Sunpharma Oral Anti-diabetes Drugs Products, Services and Solutions
5.14.4 Sunpharma Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.14.5 Sunpharma Recent Developments
5.15 Novo Nordisk
5.15.1 Novo Nordisk Profile
5.15.2 Novo Nordisk Main Business
5.15.3 Novo Nordisk Oral Anti-diabetes Drugs Products, Services and Solutions
5.15.4 Novo Nordisk Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.15.5 Novo Nordisk Recent Developments
5.16 Piramal Healthcare
5.16.1 Piramal Healthcare Profile
5.16.2 Piramal Healthcare Main Business
5.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Products, Services and Solutions
5.16.4 Piramal Healthcare Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.16.5 Piramal Healthcare Recent Developments
5.17 Bayer Healthcare
5.17.1 Bayer Healthcare Profile
5.17.2 Bayer Healthcare Main Business
5.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Products, Services and Solutions
5.17.4 Bayer Healthcare Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.17.5 Bayer Healthcare Recent Developments
5.18 Dr. Reddy’s Laboratories Ltd
5.18.1 Dr. Reddy’s Laboratories Ltd Profile
5.18.2 Dr. Reddy’s Laboratories Ltd Main Business
5.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Products, Services and Solutions
5.18.4 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.18.5 Dr. Reddy’s Laboratories Ltd Recent Developments
5.19 Glenmark Pharmaceuticals Ltd
5.19.1 Glenmark Pharmaceuticals Ltd Profile
5.19.2 Glenmark Pharmaceuticals Ltd Main Business
5.19.3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Products, Services and Solutions
5.19.4 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.19.5 Glenmark Pharmaceuticals Ltd Recent Developments
6 North America
6.1 North America Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Oral Anti-diabetes Drugs Market Dynamics
11.1 Oral Anti-diabetes Drugs Industry Trends
11.2 Oral Anti-diabetes Drugs Market Drivers
11.3 Oral Anti-diabetes Drugs Market Challenges
11.4 Oral Anti-diabetes Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Oral Anti-diabetes Drugs Market Overview
1.1.1 Oral Anti-diabetes Drugs Product Scope
1.1.2 Oral Anti-diabetes Drugs Market Status and Outlook
1.2 Global Oral Anti-diabetes Drugs Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Oral Anti-diabetes Drugs Market Size by Region (2016-2027)
1.4 Global Oral Anti-diabetes Drugs Historic Market Size by Region (2016-2021)
1.5 Global Oral Anti-diabetes Drugs Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.1 North America Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.2 Europe Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.4 Latin America Oral Anti-diabetes Drugs Market Size (2016-2027)
1.6.5 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2016-2027)
2 Oral Anti-diabetes Drugs Market Overview by Type
2.1 Global Oral Anti-diabetes Drugs Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2016-2021)
2.3 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2022-2027)
2.4 Liquid
2.5 Capsule
2.6 Tablet
3 Oral Anti-diabetes Drugs Market Overview by Distribution Channel
3.1 Global Oral Anti-diabetes Drugs Market Size by Distribution Channel: 2016 VS 2021 VS 2027
3.2 Global Oral Anti-diabetes Drugs Historic Market Size by Distribution Channel (2016-2021)
3.3 Global Oral Anti-diabetes Drugs Forecasted Market Size by Distribution Channel (2022-2027)
3.4 Hospital Pharmacies
3.5 Retail Pharmacies
3.6 Online Pharmacies
4 Oral Anti-diabetes Drugs Competition Analysis by Players
4.1 Global Oral Anti-diabetes Drugs Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Oral Anti-diabetes Drugs as of 2020)
4.3 Date of Key Players Enter into Oral Anti-diabetes Drugs Market
4.4 Global Top Players Oral Anti-diabetes Drugs Headquarters and Area Served
4.5 Key Players Oral Anti-diabetes Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Oral Anti-diabetes Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Sanofi
5.1.1 Sanofi Profile
5.1.2 Sanofi Main Business
5.1.3 Sanofi Oral Anti-diabetes Drugs Products, Services and Solutions
5.1.4 Sanofi Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.1.5 Sanofi Recent Developments
5.2 Eli Lilly
5.2.1 Eli Lilly Profile
5.2.2 Eli Lilly Main Business
5.2.3 Eli Lilly Oral Anti-diabetes Drugs Products, Services and Solutions
5.2.4 Eli Lilly Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.2.5 Eli Lilly Recent Developments
5.3 AstraZeneca plc
5.3.1 AstraZeneca plc Profile
5.3.2 AstraZeneca plc Main Business
5.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Products, Services and Solutions
5.3.4 AstraZeneca plc Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.3.5 Astellas Pharma Inc Recent Developments
5.4 Astellas Pharma Inc
5.4.1 Astellas Pharma Inc Profile
5.4.2 Astellas Pharma Inc Main Business
5.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Products, Services and Solutions
5.4.4 Astellas Pharma Inc Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.4.5 Astellas Pharma Inc Recent Developments
5.5 Johnson & Johnson (Janssen Pharmaceuticals)
5.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Profile
5.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Main Business
5.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Products, Services and Solutions
5.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Products, Services and Solutions
5.6.4 Boehringer Ingelheim Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Oral Anti-diabetes Drugs Products, Services and Solutions
5.7.4 Merck Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.7.5 Merck Recent Developments
5.8 Takeda
5.8.1 Takeda Profile
5.8.2 Takeda Main Business
5.8.3 Takeda Oral Anti-diabetes Drugs Products, Services and Solutions
5.8.4 Takeda Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.8.5 Takeda Recent Developments
5.9 Bristol Myers Squibb
5.9.1 Bristol Myers Squibb Profile
5.9.2 Bristol Myers Squibb Main Business
5.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Products, Services and Solutions
5.9.4 Bristol Myers Squibb Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.9.5 Bristol Myers Squibb Recent Developments
5.10 Novartis
5.10.1 Novartis Profile
5.10.2 Novartis Main Business
5.10.3 Novartis Oral Anti-diabetes Drugs Products, Services and Solutions
5.10.4 Novartis Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.10.5 Novartis Recent Developments
5.11 Pfizer
5.11.1 Pfizer Profile
5.11.2 Pfizer Main Business
5.11.3 Pfizer Oral Anti-diabetes Drugs Products, Services and Solutions
5.11.4 Pfizer Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.11.5 Pfizer Recent Developments
5.12 Abbott
5.12.1 Abbott Profile
5.12.2 Abbott Main Business
5.12.3 Abbott Oral Anti-diabetes Drugs Products, Services and Solutions
5.12.4 Abbott Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.12.5 Abbott Recent Developments
5.13 Biocon
5.13.1 Biocon Profile
5.13.2 Biocon Main Business
5.13.3 Biocon Oral Anti-diabetes Drugs Products, Services and Solutions
5.13.4 Biocon Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.13.5 Biocon Recent Developments
5.14 Sunpharma
5.14.1 Sunpharma Profile
5.14.2 Sunpharma Main Business
5.14.3 Sunpharma Oral Anti-diabetes Drugs Products, Services and Solutions
5.14.4 Sunpharma Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.14.5 Sunpharma Recent Developments
5.15 Novo Nordisk
5.15.1 Novo Nordisk Profile
5.15.2 Novo Nordisk Main Business
5.15.3 Novo Nordisk Oral Anti-diabetes Drugs Products, Services and Solutions
5.15.4 Novo Nordisk Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.15.5 Novo Nordisk Recent Developments
5.16 Piramal Healthcare
5.16.1 Piramal Healthcare Profile
5.16.2 Piramal Healthcare Main Business
5.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Products, Services and Solutions
5.16.4 Piramal Healthcare Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.16.5 Piramal Healthcare Recent Developments
5.17 Bayer Healthcare
5.17.1 Bayer Healthcare Profile
5.17.2 Bayer Healthcare Main Business
5.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Products, Services and Solutions
5.17.4 Bayer Healthcare Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.17.5 Bayer Healthcare Recent Developments
5.18 Dr. Reddy’s Laboratories Ltd
5.18.1 Dr. Reddy’s Laboratories Ltd Profile
5.18.2 Dr. Reddy’s Laboratories Ltd Main Business
5.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Products, Services and Solutions
5.18.4 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.18.5 Dr. Reddy’s Laboratories Ltd Recent Developments
5.19 Glenmark Pharmaceuticals Ltd
5.19.1 Glenmark Pharmaceuticals Ltd Profile
5.19.2 Glenmark Pharmaceuticals Ltd Main Business
5.19.3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Products, Services and Solutions
5.19.4 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Revenue (US$ Million) & (2016-2021)
5.19.5 Glenmark Pharmaceuticals Ltd Recent Developments
6 North America
6.1 North America Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Oral Anti-diabetes Drugs Market Dynamics
11.1 Oral Anti-diabetes Drugs Industry Trends
11.2 Oral Anti-diabetes Drugs Market Drivers
11.3 Oral Anti-diabetes Drugs Market Challenges
11.4 Oral Anti-diabetes Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
